Professional
Added to YB: 2024-03-25
Pitch date: 2023-12-31
NTRA [bullish]
Natera, Inc.
+230.24%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Market Cap
$28.0B
Pitch Price
$61.68
Price Target
N/A
Dividend
N/A
EV/EBITDA
-110.32
P/E
-119.45
EV/Sales
10.85
Sector
Biotechnology
Category
growth
Show full summary:
Alger Mid Cap Growth Fund Portfolio Holding: Natera, Inc.
NTRA: Specialty lab for genetic testing in reproductive health, oncology & transplants. Q3 beat on revenue, Signatera volume & margins drove guidance raise. Proprietary cell-free DNA platform powers prenatal (NIPT), cancer recurrence (Signatera) & organ rejection (Prospera) tests.
Read full article (1 min)